The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Colchicine in Percutaneous Coronary Intervention (Colchicine-PCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02594111
Recruitment Status : Completed
First Posted : November 1, 2015
Results First Posted : July 10, 2020
Last Update Posted : February 21, 2023
Sponsor:
Collaborator:
NYU Langone Health
Information provided by (Responsible Party):
VA Office of Research and Development

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Inflammation in the arteries of the heart may increase the risk of cardiac death. The proposed research seeks to identify the potential beneficial role of a safe anti-inflammatory medication, colchicine, on reducing damage caused by opening up a blockage in the arteries of the heart. With its quick onset of action and excellent safety profile, colchicine may have the potential to reduce risk of major adverse events related to the heart. This research also seeks to better understand the role of neutrophils, the most common type of inflammatory white blood cell in the body, when there is damage to the heart.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Acute Coronary Syndrome Drug: Colchicine vs Placebo Phase 4

Detailed Description:
The investigators will use colchicine as a tool to elucidate the role of neutrophil activation during acute vascular injury, and to explore the association between neutrophil activation and adverse cardiovascular outcomes. Colchicine reduces cell surface expression of selections, adhesion molecules key to neutrophil recruitment after vascular injury. Daily colchicine use is associated with reduced adverse cardiovascular events in stable atherosclerosis. Using a clinical percutaneous coronary intervention (PCI) model, the investigators evaluate whether pre-procedural colchicine (1.8 mg oral load over one hour) reduces the rate of post-PCI adverse cardiovascular outcomes in the context of a double-blind placebo-controlled randomized study. The investigators will also characterize neutrophil biology in acute vascular injury and the effects of colchicine on neutrophil biology in this setting.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 714 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Anti-inflammatory Therapy During Percutaneous Coronary Intervention
Actual Study Start Date : May 30, 2013
Actual Primary Completion Date : August 30, 2019
Actual Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Colchicine

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Colchicine
Colchicine 1.8 mg PO over 1 hour
 Drug: Colchicine vs Placebo
Colchicine vs Placebo 1.8 mg PO over 1 hour
Placebo Comparator: Placebo
Matching placebo
 Drug: Colchicine vs Placebo
Colchicine vs Placebo 1.8 mg PO over 1 hour


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Participants With Peri-procedural Myocardial Necrosis [ Time Frame: 24 hours ]
    troponin above the upper limit of normal (ULN)


Secondary Outcome Measures :
  1. Number of Participants With All-cause Mortality, Non-fatal MI, or Target Vessel Revascularization (TVR) [ Time Frame: 30 days ]
    all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)

  2. Number of Participants With All-cause Mortality, Non-fatal MI, or TVR [ Time Frame: 1 year ]
    all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)

  3. All-cause Mortality, Non-fatal MI, or TVR [ Time Frame: 2 years ]
    all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)

  4. All-cause Mortality, Non-fatal MI, or TVR [ Time Frame: 3 years ]
    all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)

  5. All-cause Mortality, Non-fatal MI, or TVR [ Time Frame: 4 years ]
    all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)

  6. All-cause Mortality, Non-fatal MI, or TVR [ Time Frame: 5 years ]
    all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)

  7. Number of Participants With Peri-procedural Myocardial Infarction (MI) [ Time Frame: 24 hours ]
    SCAI definition


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Referred for possible PCI

Exclusion Criteria:

  • Colchicine use within 1 month
  • History of colchicine intolerance
  • Glomerular filtration rate <30mL/minute or on dialysis (due to the need to adjust colchicine dose in this setting)
  • Active malignancy or infection (major confounder with increased inflammatory markers)
  • History of myelodysplasia (due to suggested cautionary use of colchicine in this setting)
  • High-dose statin load <24 hours prior to procedure (major confounder that is known to reduce inflammatory levels in 12 to 24 hours)
  • Use of anti-inflammatory agents (except aspirin) within 5 halflives of the individual drug
  • Use of strong Cytochrome P450, Family 3, Subfamily A, Polypeptide 4 (CYP3A4) and/or P-glycoprotein inhibitors (e.g. ritonavir, ketoconazole, clarithromycin, cyclosporine, diltiazem and verapamil, again due to drug interactions)
  • Unable to consent
  • Participating in a competing study
  • Any significant condition or situation that may put the subject at higher risk, confound the study results or interfere with adherence to study procedures
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02594111


Locations
Layout table for location information
United States, New York
Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
New York, New York, United States, 10010
Sponsors and Collaborators
VA Office of Research and Development
NYU Langone Health
Investigators
Layout table for investigator information
Principal Investigator: Binita Shah, MD Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY
  Study Documents (Full-Text)

Documents provided by VA Office of Research and Development:
Study Protocol  [PDF] August 7, 2019
Statistical Analysis Plan  [PDF] August 7, 2019

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT02594111    
Other Study ID Numbers: CARB-025-15S
First Posted: November 1, 2015    Key Record Dates
Results First Posted: July 10, 2020
Last Update Posted: February 21, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by VA Office of Research and Development:
inflammation
percutaneous coronary intervention
coronary artery disease
colchicine
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Acute Coronary Syndrome
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
 Colchicine
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents